Scholarlink

<p>In this cross-sectional study of 5.8 million US adults with hypertension taking antihypertensive single-pill combination (SPC) products in the Medical Expenditure Panel Survey (2016-2022), the median out-of-pocket cost was $5.53 per SPC fill (interquartile range [IQR] $0.00-$12.70). A hypothetical small (e.g., $4/30 days) cost cap could reduce annual out-of-pocket spending by $152.9 million overall (median savings $5.35 (IQR $1.06-$12.81) per fill). A hypothetical large cost cap (e.g., $11/30 days) could reduce annual out-of-pocket spending by $61.2 million overall (median savings $2.27 (IQR $0.00-$11.28) per fill). Despite relatively low out-of-pocket costs, these spending reductions may lower patient financial burdens associated with antihypertensive SPC therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patient out-of-pocket costs for antihypertensive single pill combination products with cost caps

  • 期刊论文

  • 发表日期：

    2026年7月4日

查看全文
  • Catherine G. Derington,
  • Kyle Tong,
  • Joshua A. Jacobs,
  • Brent M. Egan,
  • Jordan B. King,
  • Adam P. Bress,
  • Anthony Rodgers,
  • Jaejin An,
  • Kelsey B. Bryant,
  • Jordana B. Cohen,
  • Brandon K. Bellows

摘要

In this cross-sectional study of 5.8 million US adults with hypertension taking antihypertensive single-pill combination (SPC) products in the Medical Expenditure Panel Survey (2016-2022), the median out-of-pocket cost was $5.53 per SPC fill (interquartile range [IQR] $0.00-$12.70). A hypothetical small (e.g., $4/30 days) cost cap could reduce annual out-of-pocket spending by $152.9 million overall (median savings $5.35 (IQR $1.06-$12.81) per fill). A hypothetical large cost cap (e.g., $11/30 days) could reduce annual out-of-pocket spending by $61.2 million overall (median savings $2.27 (IQR $0.00-$11.28) per fill). Despite relatively low out-of-pocket costs, these spending reductions may lower patient financial burdens associated with antihypertensive SPC therapy.